Compare LPL & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPL | PBLS |
|---|---|---|
| Founded | 1985 | N/A |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.6B |
| IPO Year | 2004 | 2026 |
| Metric | LPL | PBLS |
|---|---|---|
| Price | $3.48 | $37.76 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 363.6K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.35 | N/A |
| Revenue Next Year | $2.94 | N/A |
| P/E Ratio | $25.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.76 | $25.56 |
| 52 Week High | $5.83 | $37.83 |
| Indicator | LPL | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 53.04 | 65.69 |
| Support Level | $2.76 | $26.42 |
| Resistance Level | $4.37 | N/A |
| Average True Range (ATR) | 0.12 | 2.40 |
| MACD | 0.08 | 0.22 |
| Stochastic Oscillator | 85.88 | 93.64 |
LG Display Co Ltd manufacture TFT-LCD and OLED technology-based display panels in a broad range of sizes and specifications mainly for use in IT products (comprising notebook computers, desktop monitors and tablet computers), televisions, mobile devices, including smartphones, as well as auto products, and it are one of the world's suppliers of large-sized OLED television panels. It also manufacture display panels for industrial and other applications, including entertainment systems and medical diagnostic equipment.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.